Aadi Bioscience Secures $100M to Pioneer Precision mTOR Therapies for Genetically-Defined Cancers

Aadi Bioscience, Inc. is thrilled to announce a groundbreaking funding achievement of $100,000,000 that will propel its mission to redefine cancer care through precision therapies. As a pioneering biopharmaceutical company, Aadi Bioscience focuses on genetically-defined cancers, harnessing the power of mTOR inhibition with advanced nanoparticle technology to develop transformative treatments for patients with mTOR pathway driver alterations. This significant investment will be directed toward expanding our research and development pipeline, accelerating clinical trials, and enhancing our innovative approach to precision medicine. With our lead product already receiving FDA approval for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors (PEComa), this new capital injection marks a major step forward in our quest to deliver next-generation therapies that improve patient outcomes. Our world-class leadership team, composed of seasoned industry experts from top biotech firms, brings a wealth of experience and a proven track record in advancing novel cancer therapeutics to market. With a science-first mindset and a patient-centric approach deeply embedded in our culture, we are committed to addressing the unmet needs of those battling rare and aggressive cancers. The funds will importantly support the expansion of our clinical studies, the exploration of additional therapeutic targets within the mTOR pathway, and the integration of cutting-edge nanoparticle technologies into our treatment strategies. This investment not only reinforces our commitment to innovation but also signals growing confidence in our approach to personalized cancer care. To learn more about our ongoing efforts and future directions, please visit https://aadibio.com/.